Australian public assessment report for vandetanib

The pathways of cancer that are targeted by vandetanib are (Figure 1): Indirect inhibition of tumour growth through anti angiogenic effects on endothelial cell proliferation, migration and survival; Direct inhibition of EGFR and/or RET dependent tumour growth. Figure 1: Three key signalling pathways targeted by vandetanib in cancer. Regulatory ... ................
................